IGC Pharma, Inc. $IGC

What the company doesAI summary of filing

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with primary emphasis on Alzheimer's disease. The company's lead product candidate, IGC-AD1, is currently in Phase 2 clinical trials (CALMA trial) for treatment of agitation in Alzheimer's dementia, with interim data showing statistically significant improvements compared to placebo. IGC Pharma does not currently generate revenue from pharmaceutical product sales and operates as a pre-revenue clinical-stage organization funded through equity financings and debt facilities, with expectations to continue incurring operating losses as it advances its clinical programs. The company also develops MINT-AD, an artificial intelligence platform designed to support risk stratification and longitudinal assessment in Alzheimer's disease, and maintains a portfolio of earlier-stage therapeutic candidates including TGR-63 and IGC-M3 in preclinical evaluation. [10-KT 2026-03-18]

Segments: IGC-AD1 (Phase 2 clinical trial for agitation in Alzheimer's dementia), MINT-AD (artificial intelligence platform for Alzheimer's disease risk stratification), TGR-63 (preclinical compound for amyloid plaque formation), IGC-M3 (preclinical small-molecule compound for Alzheimer's disease)